Hunan Jingfeng Pharmaceutical (000908) — Net Asset Quality Index

Latest as of September 2025: -4.3%

Hunan Jingfeng Pharmaceutical (000908) has a Net Asset Quality Index of -4.3% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥877.99 Million minus total liabilities of CN¥915.74 Million yields net assets of CN¥-37.76 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 000908 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Quality Index

-4.3%
Equity / Total Assets

Net Assets

CN¥-37.76 Million
CNY

Total Assets

CN¥877.99 Million
CNY

Total Liabilities

CN¥915.74 Million
CNY

Hunan Jingfeng Pharmaceutical Net Asset Quality Index Over Time (1995–2024)

This chart shows how Hunan Jingfeng Pharmaceutical's Net Asset Quality Index has evolved across 30 annual periods from 1995 to 2024. As of September 2025, the index stands at -4.3%, representing net assets of CN¥-37.76 Million against total assets of CN¥877.99 Million CNY. See working capital position of Hunan Jingfeng Pharmaceutical to evaluate short-term liquidity relative to the company's equity base.

Annual Net Asset Quality Index for Hunan Jingfeng Pharmaceutical (1995–2024)

The table below presents the year-by-year Net Asset Quality Index for Hunan Jingfeng Pharmaceutical from 1995 to 2024, covering 30 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hunan Jingfeng Pharmaceutical stock valuation.

Year Quality Index Net Assets (CNY) Total Assets Total Liabilities Change (pp)
2024 -1.6% CN¥-15.13 Million CN¥939.98 Million CN¥955.11 Million ▲ +12.9 pp
2023 -14.5% CN¥-153.68 Million CN¥1.06 Billion CN¥1.21 Billion ▼ -29.1 pp
2022 14.6% CN¥214.83 Million CN¥1.47 Billion CN¥1.25 Billion ▼ -3.7 pp
2021 18.3% CN¥327.73 Million CN¥1.79 Billion CN¥1.46 Billion ▼ -5.4 pp
2020 23.7% CN¥638.18 Million CN¥2.69 Billion CN¥2.05 Billion ▼ -20.9 pp
2019 44.6% CN¥1.94 Billion CN¥4.35 Billion CN¥2.41 Billion ▼ -10.1 pp
2018 54.8% CN¥2.86 Billion CN¥5.23 Billion CN¥2.37 Billion ▲ +1.4 pp
2017 53.4% CN¥2.60 Billion CN¥4.87 Billion CN¥2.27 Billion ▲ +2.5 pp
2016 50.9% CN¥2.61 Billion CN¥5.13 Billion CN¥2.52 Billion ▼ -14.4 pp
2015 65.3% CN¥2.25 Billion CN¥3.44 Billion CN¥1.19 Billion ▲ +13.4 pp
2014 51.9% CN¥994.04 Million CN¥1.91 Billion CN¥919.76 Million ▲ +50.4 pp
2013 1.6% CN¥5.31 Million CN¥336.78 Million CN¥331.47 Million ▲ +17.8 pp
2012 -16.3% CN¥-60.15 Million CN¥370.13 Million CN¥430.29 Million ▼ -16.4 pp
2011 0.2% CN¥790.82K CN¥421.45 Million CN¥420.66 Million ▼ -12.1 pp
2010 12.3% CN¥57.85 Million CN¥471.37 Million CN¥413.53 Million ▼ -0.6 pp
2009 12.8% CN¥100.67 Million CN¥784.81 Million CN¥684.14 Million ▼ -21.4 pp
2008 34.2% CN¥338.64 Million CN¥989.24 Million CN¥650.60 Million ▼ -7.1 pp
2007 41.4% CN¥336.95 Million CN¥814.38 Million CN¥477.43 Million ▲ +0.5 pp
2006 40.9% CN¥336.40 Million CN¥822.47 Million CN¥486.08 Million ▲ +1.7 pp
2005 39.2% CN¥329.66 Million CN¥840.14 Million CN¥510.48 Million ▲ +1.1 pp
2004 38.2% CN¥339.45 Million CN¥889.56 Million CN¥550.11 Million ▼ -4.5 pp
2003 42.7% CN¥419.38 Million CN¥983.02 Million CN¥563.64 Million ▼ -17.6 pp
2002 60.3% CN¥522.69 Million CN¥866.67 Million CN¥343.98 Million ▼ -20.0 pp
2001 80.3% CN¥498.41 Million CN¥620.88 Million CN¥122.47 Million ▲ +8.6 pp
2000 71.7% CN¥500.54 Million CN¥697.92 Million CN¥197.38 Million ▲ +1.6 pp
1999 70.2% CN¥485.43 Million CN¥691.94 Million CN¥206.51 Million ▼ -14.5 pp
1998 84.7% CN¥400.62 Million CN¥473.15 Million CN¥72.54 Million ▲ +19.2 pp
1997 65.4% CN¥86.51 Million CN¥132.21 Million CN¥45.70 Million ▲ +19.2 pp
1996 46.2% CN¥60.83 Million CN¥131.54 Million CN¥70.71 Million ▼ -0.2 pp
1995 46.4% CN¥30.79 Million CN¥66.33 Million CN¥35.54 Million
pp = percentage points